What’s Next for mRNA: From COVID to Cancer and Beyond

Interest in mRNA as a therapeutic modality has exploded since the approval of mRNA-based COVID-19 vaccines. “With significant data available on the safety and efficacy of mRNA vaccines, many companies are looking to further expand their pipelines beyond infectious disease to potentially develop therapies for a wide variety of other indications too.”

Learn more on the challenges of mRNA development and manufacturing, potential solutions and where the industry may go next with mRNA therapies.

Read More: solutions.catalent.com

Catalent Pharma Solutions
14 Schoolhouse Road Somerset, NJ 08873 USA
Tel. +1.888.765.8846
solutions@catalent.com
www.catalent.com